ATE100322T1 - Verwendung von uridin zur behandlung nervoeser stoerungen. - Google Patents
Verwendung von uridin zur behandlung nervoeser stoerungen.Info
- Publication number
- ATE100322T1 ATE100322T1 AT89830264T AT89830264T ATE100322T1 AT E100322 T1 ATE100322 T1 AT E100322T1 AT 89830264 T AT89830264 T AT 89830264T AT 89830264 T AT89830264 T AT 89830264T AT E100322 T1 ATE100322 T1 AT E100322T1
- Authority
- AT
- Austria
- Prior art keywords
- uridin
- treatment
- nervous disorders
- uridine
- schizophrenia
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 102100025841 Cholecystokinin Human genes 0.000 abstract 1
- 101800001982 Cholecystokinin Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 210000005013 brain tissue Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 229940107137 cholecystokinin Drugs 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT48118/88A IT1219667B (it) | 1988-06-21 | 1988-06-21 | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
| EP89830264A EP0348360B1 (de) | 1988-06-21 | 1989-06-14 | Verwendung von Uridin zur Behandlung nervöser Störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE100322T1 true ATE100322T1 (de) | 1994-02-15 |
Family
ID=11264638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89830264T ATE100322T1 (de) | 1988-06-21 | 1989-06-14 | Verwendung von uridin zur behandlung nervoeser stoerungen. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4960759A (de) |
| EP (1) | EP0348360B1 (de) |
| JP (1) | JPH0623109B2 (de) |
| KR (1) | KR900000092A (de) |
| AT (1) | ATE100322T1 (de) |
| CA (1) | CA1327003C (de) |
| DE (1) | DE68912419T2 (de) |
| IT (1) | IT1219667B (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2634374B1 (fr) * | 1988-07-19 | 1993-10-15 | Laboratoires Serobiologiques | Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi |
| WO1994026280A1 (fr) * | 1993-05-19 | 1994-11-24 | Korea Green Cross Corporation | Remede contre l'arthrite contenant de l'uridine comme ingredient actif |
| US5962459A (en) * | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| IT1290781B1 (it) * | 1996-05-28 | 1998-12-10 | Polifarma Spa | Agente attivo terapeutico per il trattamento di malattie degenerative neuronali. |
| US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| ES2294850T3 (es) * | 1998-07-31 | 2008-04-01 | Massachusetts Institute Of Technology | Tratamiento de la enfermedad de alzheimer mediante el aumento de los niveles de citidina in vivo. |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US20060069061A1 (en) * | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US7807654B2 (en) | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| US7915233B1 (en) | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| KR100758712B1 (ko) | 1999-02-23 | 2007-09-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 미토콘드리아 장애의 치료 또는 예방용 제약조성물 |
| WO2001068104A1 (en) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
| US6727231B1 (en) | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
| AUPR951101A0 (en) | 2001-12-13 | 2002-01-24 | Centre For Molecular Biology And Medicine | Method of treatment |
| JP2007508315A (ja) * | 2003-10-08 | 2007-04-05 | ザ マクレーン ホスピタル コーポレーション | ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法 |
| AU2005244816B2 (en) * | 2004-05-13 | 2011-09-29 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
| US8318798B2 (en) | 2005-11-24 | 2012-11-27 | National University Corporation Hokkaldo University | Therapeutic agent for neurodegenerative disease |
| EP1897937A1 (de) * | 2006-09-07 | 2008-03-12 | NeuroProgen GmbH Leipzig | Verfahren zur Züchtung von neuralen Vorläuferzellen |
| CN101896119A (zh) | 2007-11-02 | 2010-11-24 | 麻省理工学院 | 尿苷饮食添加顺应性方法及其用途 |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| NZ598247A (en) * | 2009-07-31 | 2014-01-31 | Clera Inc | Compositions and methods for treating parkinson’s disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1178044B (it) * | 1984-10-09 | 1987-09-03 | Polifarma Spa | Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina |
| JPH0669953B2 (ja) * | 1985-08-16 | 1994-09-07 | 日産化学工業株式会社 | 脳脊髄系神経栄養剤 |
| DE3883374T2 (de) * | 1987-10-28 | 1993-12-09 | Pro Neuron Inc | Acylatiertes uridin und cytidin und deren verwendungen. |
-
1988
- 1988-06-21 IT IT48118/88A patent/IT1219667B/it active
-
1989
- 1989-05-24 CA CA000600276A patent/CA1327003C/en not_active Expired - Fee Related
- 1989-06-13 JP JP1150354A patent/JPH0623109B2/ja not_active Expired - Fee Related
- 1989-06-14 AT AT89830264T patent/ATE100322T1/de not_active IP Right Cessation
- 1989-06-14 DE DE68912419T patent/DE68912419T2/de not_active Expired - Fee Related
- 1989-06-14 EP EP89830264A patent/EP0348360B1/de not_active Expired - Lifetime
- 1989-06-19 US US07/367,615 patent/US4960759A/en not_active Expired - Lifetime
- 1989-06-20 KR KR1019890008467A patent/KR900000092A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0348360A3 (de) | 1991-10-23 |
| KR900000092A (ko) | 1990-01-30 |
| JPH0245425A (ja) | 1990-02-15 |
| CA1327003C (en) | 1994-02-15 |
| JPH0623109B2 (ja) | 1994-03-30 |
| DE68912419D1 (de) | 1994-03-03 |
| EP0348360A2 (de) | 1989-12-27 |
| IT8848118A0 (it) | 1988-06-21 |
| EP0348360B1 (de) | 1994-01-19 |
| US4960759A (en) | 1990-10-02 |
| DE68912419T2 (de) | 1994-08-04 |
| IT1219667B (it) | 1990-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE100322T1 (de) | Verwendung von uridin zur behandlung nervoeser stoerungen. | |
| DE69012591D1 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
| DE58902094D1 (de) | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| DK0431580T3 (da) | Substituerede cyclohexanoler med virkning på centralnervesystemet | |
| DE69112895D1 (de) | Pharmazeutische Verbindungen. | |
| DE10199020I1 (de) | Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit | |
| DE69012261D1 (de) | Verwendung von Sertralin zur Behandlung verfrühter Ejakulation. | |
| EP0616032A3 (de) | Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase. | |
| DK0531155T3 (da) | Cerebralaktiverende præparat | |
| IT9041503A0 (it) | Dispositivo per la cura chirurgica dell'ametropia | |
| DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
| ATE261443T1 (de) | 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen | |
| ATE147626T1 (de) | Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung | |
| DE3780542D1 (en) | Substituierte hexahydroarylchinolizine. | |
| AU560542B2 (en) | Pyridazine derivatives which have c.n.s. activity | |
| EP0402734A3 (de) | Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung | |
| ATE230608T1 (de) | Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit | |
| ATE80998T1 (de) | Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. | |
| ATE122889T1 (de) | Verwendung von mizoribin zur behandlung oder vorbeugung der multiplen sklerose. | |
| ATE136776T1 (de) | Verwendung von heptastigmin zur behandlung der zerebralen ictus | |
| EP0402733A3 (de) | Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung | |
| ATE78160T1 (de) | Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien. | |
| PT95825A (pt) | Processo para a preparacao de composicoes farmaceuticas para a administracao transdermica contendo 2-amino-6-n-propilamino-4,5,6,7-tetra-hidrobenzotriazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |